A previous study showed that high PD-L1 expression (PD-L1 TPS ≥ 50%) in late stage non-small cell lung cancer with negative driver mutations predicted a good response to ICIs monotherapy (Reck et al. 2016). This evidence concerns the gene CD274 and non-small cell lung carcinoma.